Heidelberg Pharma AG
XETRA:HPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
NO |
|
Nitta Gelatin India Ltd
BSE:506532
|
IN |
|
B
|
Beijing Asiacom Information Technology Co Ltd
SZSE:301085
|
CN |
Heidelberg Pharma AG
Intangible Assets
Heidelberg Pharma AG
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Intangible Assets
€2.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Intangible Assets
€1.6B
|
CAGR 3-Years
94%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Intangible Assets
€12.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Intangible Assets
€1.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Intangible Assets
€16.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-12%
|
|
|
Formycon AG
XETRA:FYB
|
Intangible Assets
€444.1m
|
CAGR 3-Years
749%
|
CAGR 5-Years
368%
|
CAGR 10-Years
127%
|
|
Heidelberg Pharma AG
Glance View
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
See Also
What is Heidelberg Pharma AG's Intangible Assets?
Intangible Assets
2.7m
EUR
Based on the financial report for Nov 30, 2025, Heidelberg Pharma AG's Intangible Assets amounts to 2.7m EUR.
What is Heidelberg Pharma AG's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
-1%
Over the last year, the Intangible Assets growth was -1%. The average annual Intangible Assets growth rates for Heidelberg Pharma AG have been -1% over the past three years , -1% over the past five years .
